Lowest Price Guaranteed From USD 4,799
Published
March 2023
Pages
254
View Count
7049
Example Insights
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Report Description
The global digital manufacturing market for biologics is anticipated to grow at a compounded annual growth rate (CAGR) of 18% during the forecast period, driven mainly by the increased focus on industry 4.0 technologies. Digital transformation has also garnered the interest of pharmaceutical industry. It involves incorporating digital technologies across all functions / operations. Digital technologies have been impacting drug discovery to clinical development as well as manufacturing, amongst other functions. Since the outbreak of COVID-19 infection, there has been immense pressure on the biopharmaceutical industry to reduce production timelines and increase the manufacturing capacity, without compromising on the quality of the final product. Further, a surge in morbidity across the globe and enhanced interconnectivity of equipment and technologies has led to an increased burden on manufacturing operations. Other factors that influenced the market include higher competition, competitive pricing, inflation rate, technological advancements and evolving regulatory guidelines. These factors demanded a fundamental shift from conventional manufacturing operations, which subsequently led to the introduction of industry 4.0 technologies. Digital transformation in pharma / biopharma manufacturing has emerged as a promising alternative to mitigate a number of bioprocessing related concerns, as well as significantly promote process robustness and product quality.
Digital manufacturing of biologics, popularly known as digital biomanufacturing or bioprocessing 4.0, refers to the integration of physical equipment with digital software and platforms, such as process analytical technology(PAT), data analysis software (DAS), manufacturing execution systems (MES) and digital twin, in order to streamline the overall biomanufacturing process. Implementation of these technologies in monitoring, analytics and computing capabilities is expected to revolutionize current biomanufacturing practices. Further, digital bioprocessing is believed to have transformed manufacturing principles in areas, such as process development, operational activities, logistics and supply chain management, when used in combination with advanced technologies, including artificial intelligence (AI), machine learning and internet of things (IoT).
The Digital Manufacturing Market for Biologics: Distribution by Type of Technology (Process Analytical Technology, Data Analysis Software, Manufacturing Execution System and Digital Twin), Deployment Options (Cloud-based and On-premises), Type(s) of Biologic(s) Manufactured (Antibodies, Cell Therapies and Gene Therapies, Proteins, Vaccines, and Others), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and the likely future potential of the digital biomanufacturing market, over the forecast period. It highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key inclusions of the research report are briefly discussed below:
Breakthroughs in the biotechnology industry, over the last few decades, has provided a considerable boost to the overall development landscape of biopharmaceutical drugs. In 2022, a milestone was witnessed when the number of approvals received by biologics narrowly outpaced those reported by small molecules. Further, in the same year, nearly half of the biologic approvals were allotted to novel class of modalities, including antibody drug conjugates (ADCs), bispecific antibodies, cell therapies and gene therapies. This can be attributed to the fact that the demand for biologics has been constantly increasing and is supported by continuous innovation in this field. Specifically, advancements in niche segments is expected to culminate in accelerated growth of the biologics market.
According to a recent report, the development of a new drug takes 10-15 years, with an overall investment of USD 1-2 billion. Despite the significant investment of resources, over 90% of the candidates fail at different stages of clinical trials, resulting in huge financial losses for biomanufacturers.
As a direct consequence of the consistently growing demand for biologics and the existing challenges, there is an increase in the requirement for solutions that help in establishment of a digitally enabled and connected end-to-end process, in order to optimize bioprocess operations. Research suggests that, at present, 20% of the organizations have already adopted digitalized approaches for biomanufacturing. Such approaches are expected to enable an uninterrupted and accessible supply of cost-effective drugs that are likely to be launched commercially, with reduced development timelines. In fact, several leading biopharma players have claimed to achieve 40% increase in quality, 15% reduction in cost, 80% decrease in process variability and 20% shorter operational timelines by leveraging digital biomanufacturing advances. All these factors will drive the digital biomanufacturing market growth during the forecast period.
Currently, batch-to-batch variation and product validation are considered as major bottlenecks faced by the biologic industry. Digital biomanufacturing harnesses various advancements, such as real-time monitoring, data analytics, automation, modelling, process optimization and other digital tools to transform the available information into actionable insights. This is expected to help in the creation of a uniform process, which is capable of decreasing the deviation in quality of each batch. Other key benefits of digital biomanufacturing include improved efficiency, higher product yield, better product quality, data integrity, reduced manual intervention and limited risk of contamination. It is worth noting that digitalization in biopharmaceutical manufacturing is becoming an essential requirement, given its potential to develop enhanced quality products, with high speed, agility and sustainability. The benefits offered by digital tools in manufacturing will drive the market growth over the forecast period.
The digital biomanufacturing providers landscape features a mix of large, mid-sized and small companies, which have the required expertise and offer various digital services for the production of biologics. At present, more than 140 digital technologies have been / are being developed by over 100 industry stakeholders to enable the manufacturing of biologics. Further, various types of technologies currently facilitate smart biomanufacturing; of these, 48% are based on the principles of Process Analytical Technology, followed by those using Manufacturing Execution System (28%), Data Analysis Software (14%) and digital twin (10%).
Another digital tool supporting digital transformation of biologic manufacturing are the data analysis software. They offer wide spectrum of technical competencies, including process intelligence and data integration. We have identified more than 15 data analysis software companies established across the globe, offering 20+ data analysis software solution developed for biologic manufacturing applications.
The global digital manufacturing market for biologics is anticipated to be worth around USD 15 billion. Driven by improved data analytics, better product yield, faster production timelines, access to real time operations and rising interest in paperless manufacturing amongst innovators, lucrative opportunities are expected to emerge for players offering bioprocessing 4.0 services. The digital biomanufacturing market is anticipated to grow at a CAGR of 18%, during the forecast period 2023-2035.
In terms of type of technology, the process analytical technology market holds 35% share of the digital biomanufacturing market. Over 85% of the process analytical technology platforms are capable of offering process automation and bioprocess optimization and controls. Majority of the PAT platforms support the manufacturing of proteins and antibodies. However, in terms of market growth, the digital twin market is expected to grow at a relatively high CAGR of 27%, during the forecast period.
Many stakeholders are undertaking initiatives to forge alliance with other industry / non-industry players. It is worth highlighting that over 75 strategic partnerships related to digital biomanufacturing have been inked since 2018, indicating that software providers are actively upgrading their technology related capabilities and accommodating the current and anticipated demand for digital biomanufacturing. Given the inclination towards cutting-edge technologies, along with innovative approaches to tailor the bioprocessing, we believe that the digital biomanufacturing technologies market is likely to evolve at a rapid pace, over the forecast period. ,
Further, currently, the market for on-premise deployment options is expected to capture the majority market share; however, this trend is likely to change in the foreseen future with the rising popularity of cloud-based technologies. Nearly 80% of the manufacturing execution system companies are offering cloud-based MES solutions that can be integrated with numerous types of software to carry out production tracking, performance analysis and data integration functions. The availability of such cloud-based manufacturing execution system will drive the market size of MES market over the forecast period.
Examples of leading digital manufacturing companies engaged in this industry include (which have also been captured in this report) AspenTech, Bioreactors.net, Dassault Systèmes, FUJIFILM Diosynth Biotechnologies, GE Healthcare, Körber, Merck, Sartorius and Thermo Fisher Scientific. This market report includes an easily searchable excel database of all the companies providing process analytical technology, manufacturing execution system, data analysis software and digital twin for biologic manufacturing
Several recent developments have taken place in the field of digital manufacturing. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments as defined in the below table:
Key Report Attributes | Details | |
Base Year |
2023 |
|
Forecast Period |
2023 – 2035 |
|
CAGR |
18% |
|
Type of Technology |
|
|
Deployment Options |
|
|
Type(s) of Biologic(s)Manufactured |
|
|
Key Geographical Regions |
|
|
Key Companies Profiled |
|
|
Customization Scope |
|
|
PowerPoint Presentation (Complimentary) |
|
|
Excel Data Packs(Complimentary) |
|
The market report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this industry, across different regions. Amongst other elements, the research report includes:
One of the key objectives of the market report was to estimate the current opportunity and future growth potential of the digital biomanufacturing market. We have provided an informed estimate on the likely evolution of the market for the forecast period, 2023-2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of technology (Process Analytical Technology, Data Analysis Software, Manufacturing Execution System and Digital Twin), deployment options (cloud based and on-premises), type(s) of biologic(s) manufactured (antibodies, cell therapies and gene therapies, proteins, vaccines and others) and key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Digital Manufacturing for Biologics
3.3. Emerging Technologies that Support Digital Manufacturing
3.3.1. Process Analytical Technology (PAT)
3.3.2. Data Analysis Software (DAS)
3.3.3. Bioprocess Digital Twin
3.3.4. Manufacturing Execution System (MES)
3.4. Challenges Associated with the Adoption of Digital Manufacturing of Biologics
3.5. Future Perspectives
4. MARKERT LANDSCAPE
4.1. Chapter Overview
4.2. List of Process Analytical Technology (PAT) Companies
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region-wise)
4.2.4. Analysis by Location of Headquarters (Country-wise)
4.2.5. Analysis by Type of Company
4.2.6. Analysis by Number of Platforms Offered
4.2.7. Analysis by Deployment Options
4.2.8. Analysis by Platform Capabilities
4.2.9. Analysis by Type(s) of Biologic(s) Manufactured
4.2.10. Analysis by Other Compatible Platforms
4.2.11. Analysis by Type of End User(s)
4.2.12. Analysis by Year of Establishment, Location of Headquarters and Platform Capabilities
4.2.13. Analysis by Years of Experience, Location of Headquarters and Number of Platform Capabilities (Dot-Plot Representation)
4.3. List of Data Analysis Software (DAS) Companies
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters (Region-wise)
4.3.4. Analysis by Location of Headquarters (Country-wise)
4.3.5. Analysis by Type of Company
4.3.6. Analysis by Number of Software Offered
4.3.7. Analysis by Deployment Options
4.3.8. Analysis by Software Capabilities
4.3.9. Analysis by Other Compatible Platforms
4.3.10. Analysis by Type of End User(s)
4.3.11. Analysis by Year of Establishment, Location of Headquarters and Software Capabilities
4.3.12. Analysis by Years of Experience, Location of Headquarters and Number of Software Capabilities (Dot-Plot Representation)
4.4. List of Manufacturing Execution System (MES) Companies
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters (Region-wise)
4.4.4. Analysis by Location of Headquarters (Country-wise)
4.4.5. Analysis by Type of Company
4.4.6. Analysis by Number of Platforms Offered
4.4.7. Analysis by Deployment Options
4.4.8. Analysis by Platform Capabilities
4.4.9. Analysis by Integrating Software
4.4.10. Analysis by Type of Service(s) Offered
4.4.11. Analysis by Analysis by Years of Experience, Location of Headquarters and Number of Platform Capabilities (Dot-Plot Representation)
4.5. List of Digital Twin Companies
4.5.1. Analysis by Year of Establishment
4.5.2. Analysis by Company Size
4.5.3. Analysis by Location of Headquarters (Region-wise)
4.5.4. Analysis by Location of Headquarters (Country-wise)
4.5.5. Analysis by Number of Platforms Offered
4.5.6. Analysis by Area(s) of Application
4.5.7. Analysis by Type of End User(s)
4.5.8. Analysis by Years of Experience, Location of Headquarters and Area(s) of Application (Dot-Plot Representation)
5. TECHNOLOGY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Technology Competitiveness Analysis: Process Analytical Technologies
5.4.1. Process Analytical Technologies Offered by Small Companies
5.4.2. Process Analytical Technologies Offered by Mid-sized Companies
5.4.3. Process Analytical Technologies Offered by Large Companies
5.4.4. Process Analytical Technologies Offered by Very Large Companies
5.5. Technology Competitiveness Analysis: Data Analysis Software
5.6. Technology Competitiveness Analysis: Manufacturing Execution System
5.6.1. Manufacturing Execution Systems Offered by Small Companies
5.6.2. Manufacturing Execution Systems Offered by Mid-sized Companies
5.6.3. Manufacturing Execution Systems Offered by Large and Very Large Companies
5.7. Technology Competitiveness Analysis: Digital Twins
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. AspenTech
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Technology Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. FUJIFILM Diosynth Biotechnologies
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Technology Portfolio
6.3.4. Recent Developments and Future Outlook
6.4. Merck
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Technology Portfolio
6.4.4. Recent Developments and Future Outlook
6.5. Thermo Fisher Scientific
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Technology Portfolio
6.5.4. Recent Developments and Future Outlook
6.6. Bioreactors.net
6.6.1. Company Overview
6.6.2. Technology Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Sartorius
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Technology Portfolio
6.7.4. Recent Developments and Future Outlook
6.8. Dassault Systèmes
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Area(s) of Application
6.8.4. Recent Developments and Future Outlook
6.9. GE Healthcare
6.9.1. Company Overview
6.9.2. Technology Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Körber
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Technology Portfolio
6.10.4. Recent Developments and Future Outlook
7. BENCHMARKING ANALYSIS
7.1. Chapter Overview
7.2. Methodology and Key Assumptions
7.3. Competitive Benchmarking by Company Size and Region
7.3.1. Competitive Benchmarking: Small Players based in North America (Peer Group I)
7.3.2. Competitive Benchmarking: Mid-sized Players based in North America (Peer Group II)
7.3.3. Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
7.3.4. Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
7.3.5. Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
7.3.6. Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
7.3.7. Competitive Benchmarking: Small, Mid-sized and Very Large Players based in Asia-Pacific (Peer Group VII)
7.4. Competitive Benchmarking: Pockets of Innovation and White Spaces
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Digital Biomanufacturing: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Technology
8.3.5. Analysis by Year of Partnership and Type of Technology
8.3.6. Most Active Players: Analysis by Number of Partnerships
8.3.7. Analysis by Geography
8.3.7.1. Intracontinental and Intercontinental Agreements
8.3.7.2. International and Local Agreements
9. MARKET CONCENTRATION ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Market Concertation Analysis: Top Digital Biomanufacturing Providers
10. INDUSTRY LIFECYCLE ANALYSIS
10.1. Chapter Overview
10.2. Industry Lifecycle Analysis
10.3. Digital Biomanufacturing: Historical Timeline of Key Events
10.4. Digital Biomanufacturing: Start-up Activity
10.5. Digital Biomanufacturing: Established Players Activity
10.6. Digital Biomanufacturing: Partnership and Collaboration Trends
10.7. Digital Biomanufacturing: Funding and Investments Trends
10.8. Current Barriers to Wider Adoption of Digitalization in Biomanufacturing
10.9. Future Outlook of Digital Biomanufacturing
10.10. Industry Lifecycle Analysis: Digital Biomanufacturing
11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Digital Manufacturing Market for Biologics, 2023-2035
11.4. Digital Manufacturing Market for Biologics: Analysis by Type of Technology
11.4.1. Process Analytical Technology Market for Biologic Manufacturing, 2023-2035
11.4.2. Data Analysis Software Market for Biologic Manufacturing, 2023-2035
11.4.3. Manufacturing Execution System Market for Biologic Manufacturing, 2023-2035
11.4.4. Digital Twin Market for Biologic Manufacturing, 2023-2035
11.5. Digital Manufacturing Market for Biologics: Analysis by Type of Deployment Options
11.5.1. Market for Cloud-based Deployment Options, 2023-2035
11.5.2. Market for On-premises Deployment Options, 2023-2035
11.6. Digital Manufacturing Market for Biologics: Analysis by Type(s) of Biologic(s) Manufactured
11.6.1. Market for Antibodies, 2023-2035
11.6.2. Market for Cell and Gene Therapies, 2023-2035
11.6.3. Market for Proteins, 2023-2035
11.6.4. Market for Vaccines, 2023-2035
11.6.5. Market for Others, 2023-2035
11.7. Digital Manufacturing Market for Biologics: Analysis by Geography
11.7.1. Market in North America, 2023-2035
11.7.2. Market in Europe, 2023-2035
11.7.3. Market in Asia-Pacific, 2023-2035
11.7.4. Market in Latin America, 2023-2035
11.7.5. Market in Middle East and North Africa, 2023-2035
12. CONCLUDING REMARKS
13. INTERVIEW TRANSCRIPTS
13.1. Chapter Overview
13.2. BioIntelligence Technologies
13.2.1. Interview Transcript: Joel Sirois, Chief Executive Officer and President
13.3. Yokogawa Insilico Biotechnology
13.3.1. Interview Transcript: Klaus Mauch, Managing Director and Chief Executive Officer
13.4. Aizon
13.4.1 Company Snapshot
13.4.2. Interview Transcript: Tudor Munteanu, Vice President of Operations and Strategic Initiatives
13.5. MasterControl
13.5.1 Company Snapshot
13.5.2. Interview Transcript: Ciaran O'Keeffe, Director, Business Development and Channel Sales, and Isura Sirisena, Quality and Manufacturing Digitization Specialist
13.6. Trunovate
13.6.1 Company Snapshot
13.6.2. Interview Transcript: Yaron Halfon, Director of Sales
13.7. Dassault Systèmes
13.7.1 Company Snapshot
13.7.2. Interview Transcript: Barbara Holtz, Business Consultant
14. APPENDIX I: TABULATED DATA
15. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Overview of Digital Biomanufacturing in Healthcare
Figure 3.2 Software Capabilities in Digital Biomanufacturing
Figure 3.3 Challenges Associated with the Adoption of Digital Biomanufacturing
Figure 4.1 Digital Biomanufacturing Companies: Distribution by Type of Technology
Figure 4.2 Process Analytical Technology Companies: Distribution by Year of Establishment
Figure 4.3 Process Analytical Technology Companies: Distribution by Company Size
Figure 4.4 Process Analytical Technology Companies: Distribution by Location of Headquarters (Region-wise)
Figure 4.5 Process Analytical Technology Companies: Distribution by Location of Headquarters (Country-wise)
Figure 4.6 Process Analytical Technology Companies: Distribution by Type of Company
Figure 4.7 Process Analytical Technology Companies: Distribution by Number of Platforms Offered
Figure 4.8 Process Analytical Technology Companies: Distribution by Deployment Options
Figure 4.9 Process Analytical Technologies: Distribution by Platform Capabilities
Figure 4.10 Process Analytical Technologies: Distribution by Type(s) of Biologic(s) Manufactured
Figure 4.11 Process Analytical Technologies: Distribution by Other Compatible Platforms
Figure 4.12 Process Analytical Technology Providers: Distribution by Type of End User(s)
Figure 4.13 Process Analytical Technologies: Distribution by Year of Establishment, Location of Headquarters and Platform Capabilities
Figure 4.14 Process Analytical Technologies offered by Small Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
Figure 4.15 Process Analytical Technologies offered by Mid-sized Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
Figure 4.16 Process Analytical Technologies offered by Large Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
Figure 4.17 Process Analytical Technologies offered by Very Large Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
Figure 4.18 Data Analysis Software Companies: Distribution by Year of Establishment
Figure 4.19 Data Analysis Software Companies: Distribution by Company Size
Figure 4.20 Data Analysis Software Companies: Distribution by Location of Headquarters (Region-wise)
Figure 4.21 Data Analysis Software Companies: Distribution by Location of Headquarters (Country-wise)
Figure 4.22 Data Analysis Software Companies: Distribution by Type of Company
Figure 4.23 Data Analysis Software Companies: Distribution by Number of Software Offered
Figure 4.24 Data Analysis Software Companies: Distribution by Deployment Options
Figure 4.25 Data Analysis Software: Distribution by Software Capabilities
Figure 4.26 Data Analysis Software: Distribution by Other Compatible Platforms
Figure 4.27 Data Analysis Providers: Distribution by Type of End User(s)
Figure 4.28 Data Analysis Software: Distribution by Year of Establishment, Location of Headquarters and Software Capabilities
Figure 4.29 Data Analysis Software Providers: Distribution by Years of Experience, Location of Headquarters and Number of Software Capabilities
Figure 4.30 Manufacturing Execution System Companies: Distribution by Year of Establishment
Figure 4.31 Manufacturing Execution System Companies: Distribution by Company Size
Figure 4.32 Manufacturing Execution System Companies: Distribution by Location of Headquarters (Region-wise)
Figure 4.33 Manufacturing Execution System Companies: Distribution by Location of Headquarters (Country-wise)
Figure 4.34 Manufacturing Execution System Companies: Distribution by Type of Company
Figure 4.35 Manufacturing Execution System Companies: Distribution by Number of Platforms Offered
Figure 4.36 Manufacturing Execution System Companies: Distribution by Deployment Options
Figure 4.37 Manufacturing Execution Systems: Distribution by Platform Capabilities
Figure 4.38 Manufacturing Execution Systems: Distribution by Integrating Software
Figure 4.39 Manufacturing Execution Systems: Distribution by Types of Service(s) Offered
Figure 4.40 Manufacturing Execution Systems Offered by Small Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
Figure 4.41 Manufacturing Execution Systems Offered by Mid-sized Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
Figure 4.42 Manufacturing Execution Systems offered by Large and Very Large Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
Figure 4.43 Digital Twin Companies: Distribution by Year of Establishment
Figure 4.44 Digital Twin Companies: Distribution by Company Size
Figure 4.45 Digital Twin Companies: Distribution by Location of Headquarters (Region-wise)
Figure 4.46 Digital Twin Companies: Distribution by Location of Headquarters (Country-wise)
Figure 4.47 Digital Twin Companies: Distribution by Number of Platforms Offered
Figure 4.48 Digital Twin Technologies: Distribution by Area(s) of Application
Figure 4.49 Digital Twin Companies: Distribution by Type of End User(s)
Figure 4.50 Digital Twin Companies: Distribution by Years of Experience, Location of Headquarters and Area(s) of Application
Figure 5.1 Process Analytical Technologies Offered by Small Companies
Figure 5.2 Process Analytical Technologies Offered by Mid-sized Companies
Figure 5.3 Process Analytical Technologies Offered by Large Companies
Figure 5.4 Process Analytical Technologies Offered by Very Large Companies
Figure 5.5 Technology Competitiveness Analysis: Data Analysis Software
Figure 5.6 Manufacturing Execution Systems Offered by Small Companies
Figure 5.7 Manufacturing Execution Systems Offered by Mid-sized Companies
Figure 5.8 Manufacturing Execution Systems Offered by Large and Very Large Companies
Figure 5.9 Technology Competitiveness Analysis: Digital Twins Technologies
Figure 6.1 AspenTech: Annual Revenues, FY 2020-3M 2023 (USD Million)
Figure 6.2 AspenTech: Technology Capabilities
Figure 6.3 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2018-H1 2022 (USD Million)
Figure 6.4 FUJIFILM Diosynth Biotechnologies: Technology Capabilities
Figure 6.5 Merck: Annual Revenues, FY 2018-9M 2022 (USD Billion)
Figure 6.6 Merck: Technology Capabilities
Figure 6.7 Thermo Fisher Scientific: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Figure 6.8 Thermo Fisher Scientific: Technology Capabilities
Figure 6.9 Bioreactors.net: Technology Capabilities
Figure 6.10 Sartorius: Annual Revenues, FY 2017-FY 2022 (USD Million)
Figure 6.11 Sartorius: Technology Capabilities
Figure 6.12 Dassault Systèmes: Annual Revenues, FY 2017-FY 2021 (USD Billion)
Figure 6.13 Dassault Systèmes: Area(s) of Application(s)
Figure 6.14 GE Healthcare: Technology Capabilities
Figure 6.15 Körber: Annual Revenues, FY 2019-FY 2021 (USD Million)
Figure 6.16 Körber: Technology Capabilities
Figure 7.1 Benchmark Analysis: Distribution by Company Size and Region
Figure 7.2 Competitive Benchmarking: Small Players based in North America (Peer Group I)
Figure 7.3 Competitive Benchmarking: Mid-sized Players based in North America (Peer Group II)
Figure 7.4 Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
Figure 7.5 Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
Figure 7.6 Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
Figure 7.7 Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
Figure 7.8 Competitive Benchmarking: Small, Mid-sized, Large and Very Large Players based in Asia-Pacific (Peer Group VII)
Figure 7.9 White Spaces: Distribution of Peer Groups by Type of Technology and Type of Company
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Technology
Figure 8.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Technology
Figure 8.6 Most Active Players: Distribution by Number of Partnerships
Figure 8.7 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 8.8 Partnerships and Collaborations: International and Local Agreements
Figure 9.1 Market Concertation Analysis: Comparison of Key Offerings of Top Digital Biomanufacturing Providers
Figure 10.1 Digital Biomanufacturing: Historical Timeline of Key Events
Figure 10.2 Digital Biomanufacturing: Start-up Activity
Figure 10.3 Digital Biomanufacturing: Established Players Activity
Figure 10.4 Digital Biomanufacturing: Partnership and Collaboration Trends
Figure 10.5 Digital Biomanufacturing: Funding and Investments Trends
Figure 10.6 Current Barriers to Wider Adoption of Digitalization in Biomanufacturing
Figure 10.7 Future Outlook of Digital Biomanufacturing
Figure 10.8 Industry Lifecycle Analysis: Digital Biomanufacturing
Figure 11.1 Global Digital Manufacturing Market for Biologics, 2023-2035 (USD Million)
Figure 11.2 Digital Manufacturing Market for Biologics: Distribution by Type of Technology, 2023 and 2035
Figure 11.3 Process Analytical Technology Market for Biologic Manufacturing, 2023-2035 (USD Million)
Figure 11.4 Data Analysis Software Market for Biologic Manufacturing, 2023-2035 (USD Million)
Figure 11.5 Manufacturing Execution System Market for Biologic Manufacturing, 2023-2035 (USD Million)
Figure 11.6 Digital Twin Market for Biologic Manufacturing, 2023-2035 (USD Million)
Figure 11.7 Digital Manufacturing Market for Biologics: Distribution by Type of Deployment Options, 2023 and 2035
Figure 11.8 Digital Biomanufacturing Market for Cloud-based Deployment Options, 2023-2035 (USD Million)
Figure 11.9 Digital Biomanufacturing Market for On-premises Deployment Options, 2023-2035 (USD Million)
Figure 11.10 Digital Manufacturing Market for Biologics: Distribution by Type(s) of Biologic(s) Manufactured, 2023 and 2035
Figure 11.11 Digital Manufacturing Market for Antibodies, 2023-2035 (USD Million)
Figure 11.12 Digital Manufacturing Market for Cell and Gene Therapies, 2023-2035 (USD Million)
Figure 11.13 Digital Manufacturing Market for Proteins, 2023-2035 (USD Million)
Figure 11.14 Digital Manufacturing Market for Vaccines, 2023-2035 (USD Million)
Figure 11.15 Digital Manufacturing Market for Others, 2023-2035 (USD Million)
Figure 11.16 Digital Manufacturing Market for Biologics: Distribution by Geography, 2023 and 2035
Figure 11.17 Digital Biomanufacturing Market in North America, 2023-2035 (USD Million)
Figure 11.18 Digital Biomanufacturing Market in Europe, 2023-2035 (USD Million)
Figure 11.19 Digital Biomanufacturing Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 11.20 Digital Biomanufacturing Market in Latin America, 2023-2035 (USD Million)
Figure 11.21 Digital Biomanufacturing Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 12.1 Concluding Remarks: Market Overview of Process Analytical Technologies
Figure 12.2 Concluding Remarks: Market Overview of Data Analysis Software
Figure 12.3 Concluding Remarks: Market Overview of Manufacturing Execution Systems
Figure 12.4 Concluding Remarks: Market Overview of Digital Twins
Figure 12.5 Concluding Remarks: Partnerships and Collaborations
Figure 12.6 Concluding Remarks: Market Forecast and Opportunity Analysis
Table 4.1 List of Process Analytical Technology Companies
Table 4.2 Process Analytical Technology Companies: Information on Platform and Deployment Options
Table 4.3 Process Analytical Technologies: Information on Platform Capabilities
Table 4.4 Process Analytical Technologies: Information on Type(s) of Biologic(s) Manufactured, Other Compatible Platforms and Type of End User(s)
Table 4.5 List of Data Analysis Software Companies
Table 4.6 Data Analysis Software Companies: Information on Deployment Options
Table 4.7 Data Analysis Software: Information on Software Capabilities
Table 4.8 Data Analysis Software: Information on Type of Biologic(s) Manufactured, Other Compatible Platforms and Type of End User(s)
Table 4.9 List of Manufacturing Execution System Companies
Table 4.10 Manufacturing Execution System Companies: Information on Deployment Options
Table 4.11 Manufacturing Execution Systems: Information on Platform Capabilities
Table 4.12 Manufacturing Execution Systems: Information on Area(s) of Application and Type of End User(s)
Table 4.13 List of Digital Twin Companies
Table 4.14 Digital Twins Technologies: Information on Area(s) of Application and Type of End User(s)
Table 5.1 Technology Competitiveness Analysis: Information on Peer Groups
Table 6.1 List of Companies Profiled
Table 6.2 AspenTech: Company Snapshot
Table 6.3 AspenTech: Recent Developments and Future Outlook
Table 6.4 FUJIFILM Diosynth Biotechnologies: Company Snapshot
Table 6.5 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 6.6 Merck: Company Snapshot
Table 6.7 Merck: Recent Developments and Future Outlook
Table 6.8 Thermo Fisher Scientific: Company Snapshot
Table 6.9 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 6.10 Bioreactors.net: Company Snapshot
Table 6.11 Sartorius: Company Snapshot
Table 6.12 Sartorius: Recent Developments and Future Outlook
Table 6.13 Dassault Systèmes: Company Snapshot
Table 6.14 GE Healthcare: Company Snapshot
Table 6.15 GE Healthcare: Recent Developments and Future Outlook
Table 6.16 Körber: Company Snapshot
Table 6.17 Körber: Recent Developments and Future Outlook
Table 7.1 Benchmark Analysis: Information on Peer Groups
Table 8.1 Digital Biomanufacturing: List of Partnerships and Collaborations, 2018-2022
Table 8.2 Digital Biomanufacturing: Information on Type of Agreement (Country-wise and Continent-wise), 2018-2022
Table 9.1 Market Concertation Analysis: Information on Years of Entrance and Key Offerings of Top Digital Biomanufacturing Providers
Table 10.1 Industry Lifecycle Analysis
Table 10.2 Industry Lifecycle Analysis: Digital Biomanufacturing
Table 13.1 BioIntelligence Technologies: Company Snapshot
Table 13.2 Yokogawa Insilico Biotechnology: Company Snapshot
Table 13.3 MasterControl: Company Snapshot
Table 13.4 Trunovate: Company Snapshot
Table 13.5 Dassault Systèmes: Company Snapshot
Table 14.1 Digital Biomanufacturing Companies: Distribution by Type of Technology
Table 14.2 Process Analytical Technology Companies: Distribution by Year of Establishment
Table 14.3 Process Analytical Technology Companies: Distribution by Company Size
Table 14.4 Process Analytical Technology Companies: Distribution by Location of Headquarters (Region-wise)
Table 14.5 Process Analytical Technology Companies: Distribution by Location of Headquarters (Country-wise)
Table 14.6 Process Analytical Technology Companies: Distribution by Type of Company
Table 14.7 Process Analytical Technology Companies: Distribution by Number of Platforms Offered
Table 14.8 Process Analytical Technology Companies: Distribution by Deployment Options
Table 14.9 Process Analytical Technologies: Distribution by Platform Capabilities
Table 14.10 Process Analytical Technologies: Distribution by Type(s) of Biologic(s) Manufactured
Table 14.11 Process Analytical Technologies: Distribution by Other Compatible Platforms
Table 14.12 Process Analytical Technology Providers: Distribution by Type of End User(s)
Table 14.13 Process Analytical Technologies: Distribution by Year of Establishment, Location of Headquarters and Platform Capabilities
Table 14.14 Data Analysis Software Companies: Distribution by Year of Establishment
Table 14.15 Data Analysis Software Companies: Distribution by Company Size
Table 14.16 Data Analysis Software Companies: Distribution by Location of Headquarters (Region-wise)
Table 14.17 Data Analysis Software Companies: Distribution by Location of Headquarters (Country-wise)
Table 14.18 Data Analysis Software Companies: Distribution by Type of Company
Table 14.19 Data Analysis Software Companies: Distribution by Number of Software Offered
Table 14.20 Data Analysis Software Companies: Distribution by Deployment Options
Table 14.21 Data Analysis Software: Distribution by Software Capabilities
Table 14.22 Data Analysis Software: Distribution by Other Compatible Platforms
Table 14.23 Data Analysis Providers: Distribution by Type of End User(s)
Table 14.24 Data Analysis Software: Distribution by Year of Establishment, Location of Headquarters and Software Capabilities
Table 14.25 Manufacturing Execution System Companies Distribution by Year of Establishment
Table 14.26 Manufacturing Execution System Companies: Distribution by Company Size
Table 14.27 Manufacturing Execution System Companies: Distribution by Location of Headquarters (Region-wise)
Table 14.28 Manufacturing Execution System Companies: Distribution by Location of Headquarters (Country-wise)
Table 14.29 Manufacturing Execution System Companies: Distribution by Type of Company
Table 14.30 Manufacturing Execution System Companies: Distribution by Number of Platforms Offered
Table 14.31 Manufacturing Execution System Companies: Distribution by Deployment Options
Table 14.32 Manufacturing Execution Systems: Distribution by Platform Capabilities
Table 14.33 Manufacturing Execution Systems: Distribution by Integrating Software
Table 14.34 Manufacturing Execution Systems: Distribution by Types of Service(s) Offered
Table 14.35 Digital Twin Companies: Distribution by Year of Establishment
Table 14.36 Digital Twin Companies: Distribution by Company Size
Table 14.37 Digital Twin Companies: Distribution by Location of Headquarters (Region-wise)
Table 14.38 Digital Twin Companies: Distribution by Location of Headquarters (Country- wise)
Table 14.39 Digital Twin Companies: Distribution by Number of Platforms Offered
Table 14.40 Digital Twins Technologies: Distribution by Area(s) of Application
Table 14.41 Digital Twin Companies: Distribution by Type of End User(s)
Table 14.42 AspenTech: Annual Revenues, FY 2020-3M 2023 (USD Million)
Table 14.43 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2018-H1 2022 (USD Million)
Table 14.44 Merck: Annual Revenues, FY 2018-9M 2022 (USD Billion)
Table 14.45 Thermo Fisher Scientific: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Table 14.46 Sartorius: Annual Revenues, FY 2017-FY 2022 (USD Million)
Table 14.47 Dassault Systèmes: Annual Revenues, FY 2017-FY 2021 (USD Billion)
Table 14.48 Körber: Annual Revenues, FY 2019-FY 2021 (USD Million)
Table 14.49 Benchmark Analysis: Distribution by Company Size and Region
Table 14.50 Partnerships and Collaborations: Distribution by Year of Partnership
Table 14.51 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.52 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 14.53 Partnerships and Collaborations: Distribution by Type of Technology
Table 14.54 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Technology
Table 14.55 Most Active Players: Distribution by Number of Partnerships
Table 14.56 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 14.57 Partnerships and Collaborations: International and Local Agreements
Table 14.58 Digital Biomanufacturing: Start-up Activity
Table 14.59 Global Digital Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.60 Digital Manufacturing Market for Biologics: Distribution by Type of Technology, 2023 and 2035
Table 14.61 Process Analytical Technology Market for Biologic Manufacturing, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.62 Data Analysis Software Market for Biologic Manufacturing, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.63 Manufacturing Execution System Market for Biologic Manufacturing, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.64 Digital Twin Market for Biologic Manufacturing, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.65 Digital Manufacturing Market for Biologic: Distribution by Type of Deployment Options, 2023 and 2035
Table 14.66 Digital Biomanufacturing Market for Cloud-based Deployment Options, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.67 Digital Biomanufacturing Market for On-premises Deployment Options, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.68 Digital Manufacturing Market for Biologic: Distribution by Type(s) of Biologic(s) Manufactured, 2023 and 2035
Table 14.69 Digital Manufacturing Market for Antibodies, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.70 Digital Manufacturing Market for Cell and Gene Therapies, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.71 Digital Manufacturing Market for Proteins, Conservative, Base and OptimisticScenario, 2023-2035 (USD Million)
Table 14.72 Digital Manufacturing Market for Vaccines, Conservative, Base and OptimisticScenario, 2023-2035 (USD Million)
Table 14.73 Digital Manufacturing Market for Others, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.74 Digital Manufacturing Market for Biologics: Distribution by Geography, 2023 and 2035
Table 14.75 Digital Manufacturing Market in North America, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.76 Digital Manufacturing Market in Europe, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.77 Digital Manufacturing Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.78 Digital Manufacturing Market in Latin America, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.79 Digital Manufacturing Market in Middle East and North Africa, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
Source 1: https://bioprocessintl.com/manufacturing/information-technology/the-era-of-digital-biomanufacturing/
Source 2: https://www.nature.com/articles/s41587-022-01630-6